StephanAGruppMDPhD

Pediatric Hematology & Oncology • Philadelphia, PA

Pediatric Hematologic Oncology, Pediatric Solid Tumor Oncology

Professor, Pediatrics, Perelman School of Medicine

Overview of Dr. Grupp

Dr. Stephan Grupp is a pediatric hematologist/oncologist in Philadelphia, PA and is affiliated with Children's Hospital of Philadelphia. He received his medical degree from University of Cincinnati College of Medicine and has been in practice 30 years. Dr. Grupp accepts several types of health insurance, listed below. He is one of 166 doctors at Children's Hospital of Philadelphia who specialize in Pediatric Hematology & Oncology. He has more than 100 publications and over 500 citings.

Office
3401 Civic Center Blvd
# Children
Philadelphia, PA 19104
Book by Phone+1(267) 369-5927

Fax+1 215-590-3992

Education & Training

Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1989 - 1991
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1987 - 1989
University of Cincinnati College of MedicineClass of 1987

Certifications & Licensure

PA State Medical License 1996 - 2024
MA State Medical License 1989 - 1997
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Philadelphia Magazine Castle Connolly, 2005-2006, 2008, 2011
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma Start of enrollment: 2001 Apr 01
Completed
Phase 2
Sirolimus for Autoimmune Disease of Blood Cells Start of enrollment: 2006 Dec 01
Completed
Phase 1, Phase 2
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases Start of enrollment: 2007 Dec 31
Completed
Phase 3
CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation for T and B Cell Depletion Start of enrollment: 2005 Jan 01
Completed
Phase 2
Collection of Bone Marrow From Donors Treated With or Without Filgrastim Start of enrollment: 2010 Jun 14
Completed
Phase 3
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Start of enrollment: 2012 Sep 27
Completed
Phase 1
Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma Start of enrollment: 2011 Aug 17
Completed
Phase 1, Phase 2
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Start of enrollment: 2014 Aug 14
Completed
Phase 2
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Start of enrollment: 2015 Apr 08
Completed
Phase 2
CD22 Redirected Autologous T Cells for ALL Start of enrollment: 2016 Jan 13
Recruiting
Phase 1
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome Start of enrollment: 2016 Aug 01
Completed
Phase 1
Unrelated And Partially Matched Related Donor PSCT w/ T Cell Receptor (TCR) αβ Depletion for Patients With BMF Start of enrollment: 2017 Feb 01
Recruiting
Not Applicable
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases Start of enrollment: 2024 Dec 01
Recruiting
Phase 2
Pediatric GVHD Low Risk Steroid Taper Trial Start of enrollment: 2022 Oct 20
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy.
Barbara D Friedes, Amanda M DiNofia, Emma Iannone, Yimei Li, Susan R Rheingold
Blood Advances. 2024-11-20
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks.
Caroline Diorio, David T Teachey, Stephan A Grupp
Nature Reviews. Clinical Oncology. 2024-11-15
TET2 regulates early and late transitions in exhausted CD8T cell differentiation and limits CAR T cell function.
Alexander J Dimitri, Amy E Baxter, Gregory M Chen, Caitlin R Hopkins, Geoffrey T Rouin
Science Advances. 2024-11-15

Journal Articles

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Β-thalassemia
Haydar Frangoul, Jennifer Domm, Stephan Grupp, Rupert Handgretinger, The New England Journal of Medicine
Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell
Vijay G Bhoj, David M Barrett, Carl H June, Stephan A Grupp, David E Ambrose, Saar I Gill, Marco Ruella, Bruce L Levine, Shannon L Maude, Nature
Genetic Mechanisms of Target Antigen Loss in CAR19 Therapy of Acute Lymphoblastic Leukemia
John E Levine, Muna Qayed, Stephan A Grupp, Eneida R Nemecek, Stella M Davies, Michael R Verneris, Michael Boyer, Jeffrey A Engelman, Nature
Veno-Occlusive Disease After High-Dose Busulfan–Melphalan in Neuroblastoma
Gregory Yanik, Morris Kletzel, Stephan Grupp, David Jacobsohn, Christopher C Dvorak, Alix E Seif, Mark Ranalli, Haydar Frangoul, Nature
CAR-T in the Clinic: Drive with Care
Stephan Grupp, MD, Nature
Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma
Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood
High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
Stephan A Grupp, Zissimos Mourelatos, Michael C Milone, David M Barrett, Sarah A Richman, Clinical Cancer Research
Join now to see all

Abstracts/Posters

Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019
Stephan Grupp, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
Stephan Grupp, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy
Stephan Grupp, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy
Stephan Grupp, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prediction of Patients at Risk of CD19Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia
Stephan Grupp, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
Stephan Grupp, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Medical Crossfire¬: Case Studies in AYA and Adult Acute Lymphoblastic Leukemia _ How the Experts Think and Treat
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphobl...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
How the Experts Treat Acute Lymphocytic Leukemia: Case Discussions From Adolescent to Adult
60th American Society of Hematology Annual Meeting - 11/30/2018
CAR T Cells: How and How Well They Work in Acute Lymphoblastic Leukemia
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

Children's Hospital of Philadelphia Launches Global Partnership to Establish a CAR-T Therapy Program in BrazilNovember 7th, 2024
Study Reveals Possible Key to Long-Term Survival Among CAR T Therapy PatientsSeptember 25th, 2024
First Day of a ‘New Life’ for a Boy with Sickle CellSeptember 16th, 2024
Join now to see all

Grant Support

Determinants Of Relapse Risk After BMT For AllNational Cancer Institute2007–2011
Use Of Mtor Inhibitors In B Cell LeukemiaNational Cancer Institute2005–2009
Post Transplant T Cell Reconstitution In NeuroblastomaNational Cancer Institute2004–2005
Evolution Of B Precursor Leukemia In The Eu-Ret MouseNational Cancer Institute1999–2003
BCR Complex In B Cell Development And Allelic ExclusionNational Institute Of Allergy And Infectious Diseases1996–2000

Professional Memberships

American Academy of Pediatrics - AAP
Member
American Society of Hematology - ASH
Member
Children's Oncology Group
Chair, Stem Cell Transplant Discipline
American Society of Blood and Marrow Transplantation
Member

Industry Relationships

Consultant, Pfizer
Consultant, Jazz
Consultant, Novartis

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AmeriHealth Direct POS
AmeriHealth Direct POS Value Network
Amerihealth HMO
AmeriHealth HMO Value Network
AmeriHealth PPO
AmeriHealth PPO Value Network
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Carelink Health Plans PPO
Great West PPO
Horizon BCBS Direct Access
Horizon BCBS HMO
Horizon BCBS POS
Horizon BCBS PPO
Humana ChoiceCare Network PPO
IBC Keystone HMO / POS
IBC Personal Choice PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment